-
Rain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their Views
Tuesday, May 23, 2023 - 11:19am | 676Read More...Shares of Rain Oncology Inc (NASDAQ: RAIN) recovered in early trading on Tuesday, after having plummeted on disappointing cancer study data. Here are some key analyst takeaways from the company’s decision to halt studies for its lead candidate as a treatment for dedifferentiated (DD)...
-
Why Intellia Therapeutics Stock Is Soaring Today
Monday, June 28, 2021 - 8:49am | 410Read More...Intellia Therapeutics Inc (NASDAQ: NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported positive interim data from an ongoing Phase...
-
Is Celgene Risking Too Much For Too Little By Partnering With Juno Therapeutics?
Tuesday, June 30, 2015 - 3:55pm | 353Read More...Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics Inc (NASDAQ: JUNO) announced a 10-year collaborative partnership for developing and commercializing T-cell immunotherapy. As part of this partnership, Celgene has provided $150 million to Juno in cash and has also bought stake worth in the...
